[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582421":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":28,"responsibleParty":48,"collaborators":50,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"East and North Hertfordshire NHS Trust","OTHER_GOV",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Prostate cancer patients",null,"histologically proven primary or recurrent prostate cancer",{"label":13,"type":10,"description":14,"interventionNames":10},"Gynaecological cancer patient","locally advanced gynaecological malignancy in the primary and recurrent setting",[16],{"name":17,"affiliation":5,"role":18},"Peter Hoskin","PRINCIPAL_INVESTIGATOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Rishma Bhatti","CONTACT","0203 826 2020","mvccresearch\u002Fenh-tr@nhs.net",{"name":26,"role":22,"phone":10,"phoneExt":10,"email":27},"Amani Chowdhury","amani.chowdhury@nhs.net",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Mount Vernon Cancer Centre","RECRUITING","Northwood","Middlesex","HA62RN","United Kingdom","UK",{"type":38,"coordinates":39},"Point",[40,41],-0.42454,51.61162,{"lat":41,"lon":40},[44,47],{"name":21,"role":22,"phone":45,"phoneExt":10,"email":46},"02038262075","mvccresearch.enh-tr@nhs.net",{"name":17,"role":18,"phone":10,"phoneExt":10,"email":10},{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[51],{"name":52,"class":53},"TRUEinvivo Limited","UNKNOWN","100582421","in-vivo-dosimetry-for-brachytherapy-study-100582421",false,"NCT06863090","In Vivo Dosimetry for Brachytherapy Study","A Single-centre Feasibility Study Investigating the Use of in Vivo Dosimetry in Patients Receiving High Dose Rate (HDR) Brachytherapy for Gynaecological and Prostate Cancers","Inclusion Criteria:\n\n* Patients aged 18 years and above\n* Patients receiving HDR brachytherapy using iridium-192 (192Ir) radioactive source either as a monotherapy or in combination with external beam radiotherapy for:\n\n  1. histologically\u002Fradiologically proven primary or locally recurrent prostate cancer\n  2. locally advanced gynaecological malignancy in the primary and recurrent setting\n\n     * primary cervix carcinoma (squamous, adenocarcinoma, adenosquamous) FIGO IB2-IVA\n     * primary vulval FIGO I-IVA\n     * primary vaginal FIGO I-IVA\n     * primary endometrial cancer FIGO Stage I-IVA (not suitable for surgery)\n     * endometrial cancer receiving adjuvant vaginal vault brachytherapy\n     * recurrent cervix, vulval, vaginal or endometrial cancer suitable for brachytherapy as discussed in a regional gynae-oncology multidisciplinary meeting.\n* World Health Organisation (WHO) or Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\nExclusion Criteria:\n\n* Previous brachytherapy exposure to the treatment site\n* Patients unable to give informed consent\n* Patients unable to have a regional or general anaesthetic\n* Patients with the following medical conditions: coagulopathies, history of another primary malignancy, known allergy or sensitivity to study materials; previous or current fistulae\n* Not able to understand the implications of participating in the study in English\n* Patients with recent (within the last 6 months) or currently participating in interventional research","ALL","18 Years",{"count":64,"type":65},20,"ESTIMATED","OBSERVATIONAL","The main study aim is the investigate the clinical use of in vivo dosimeters (small measurement devices) for brachytherapy (internal radiotherapy).",[69,70],"Prostate Cancer","Gynaecological Cancer","2025-03-07",{"date":73,"type":74},"2025-03-11","ACTUAL",{"date":76,"type":65},"2025-03-03",{"date":78,"type":65},"2026-03-01",{"name":5,"class":6},1]